Show Summary Details
Page of

Device therapy: which devices and for whom? 

Device therapy: which devices and for whom?
Device therapy: which devices and for whom?

Roy S. Gardner

, Theresa A. McDonagh

, and Niki L. Walker

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2020. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 22 February 2020

The majority of patients with heart failure stabilize or improve with pharmacological therapy. Device therapy in heart failure addresses two potential consequences of left ventricular dysfunction, namely malignant ventricular arrhythmias that can lead to sudden cardiac death (SCD), and ventricular dyssynchrony. These two phenomena can coexist in the CHF patient. Cardiac resynchronization therapy (CRT) has a clear role in selected patients with advanced heart failure who remain symptomatic despite maximum tolerated pharmacological therapy. Implantable cardiac defibrillators (ICD) have also been shown to reduce arrhythmic deaths in both ischaemic and non-ischaemic cardiomyopathy. CRT can be combined with ICD functions (Cardiac Resynchronization Therapy-Defibrillator: CRT-D) to achieve the benefits of both devices. This chapter presents the evidence for the use of these devices, and summarizes the latest recommendations for the clinical guidelines.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.